Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 11Recruiting 11Not yet recruiting 7Completed 5Active not recruiting 4Terminated 3Withdrawn 1

Sponsor Class

OTHER 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 307Pancreatic Neoplasms 206Stomach Neoplasms 162Carcinoma, Hepatocellular 160Colonic Neoplasms 115Rectal Neoplasms 104Esophageal Neoplasms 91Carcinoma, Non-Small-Cell Lung 91Breast Neoplasms 76Neoplasms 67Liver Neoplasms 62Ovarian Neoplasms 60Melanoma 51Neoplasm Metastasis 50Cholangiocarcinoma 49Lung Neoplasms 48Squamous Cell Carcinoma of Head and Neck 37Esophageal Squamous Cell Carcinoma 37Gastrointestinal Neoplasms 36Carcinoma, Renal Cell 35Prostatic Neoplasms 33Uterine Cervical Neoplasms 32Sarcoma 32Endometrial Neoplasms 32Biliary Tract Neoplasms 31Anus Neoplasms 30Head and Neck Neoplasms 27Urinary Bladder Neoplasms 22Triple Negative Breast Neoplasms 21Adenocarcinoma Of Esophagus 21

Interventions

trastuzumab deruxtecan 1sintilimab 1pembrolizumab 1durvalumab 1cabozantinib 1Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Gastric Adenocarcinoma × Gastrointestinal × Clear all
NCT05034887 2026-04-08

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

National Cancer Center Hospital East

Phase 2 Active not recruiting
64 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT04164979 2025-08-11

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 2 Active not recruiting
34 enrolled 11 charts
Gastrointestinal

Gastric Adenocarcinoma

NCT06938139 2025-04-22

Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy

Fujian Medical University

Active not recruiting
90,000 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT06667050 2024-10-31

CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

West China Hospital

Phase 2 Active not recruiting
58 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡